DE122008000050I2 - Difluoroprostaglandin-Derivate und ihre Anwendung - Google Patents

Difluoroprostaglandin-Derivate und ihre Anwendung

Info

Publication number
DE122008000050I2
DE122008000050I2 DE122008000050C DE122008000050C DE122008000050I2 DE 122008000050 I2 DE122008000050 I2 DE 122008000050I2 DE 122008000050 C DE122008000050 C DE 122008000050C DE 122008000050 C DE122008000050 C DE 122008000050C DE 122008000050 I2 DE122008000050 I2 DE 122008000050I2
Authority
DE
Germany
Prior art keywords
group
medicine
difluoroprostaglandin
derivatives
difluoroprostaglandin derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE122008000050C
Other languages
German (de)
English (en)
Other versions
DE122008000050I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
AGC Inc
Original Assignee
Asahi Glass Co Ltd
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27301396&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122008000050(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Asahi Glass Co Ltd, Santen Pharmaceutical Co Ltd filed Critical Asahi Glass Co Ltd
Publication of DE122008000050I1 publication Critical patent/DE122008000050I1/de
Publication of DE122008000050I2 publication Critical patent/DE122008000050I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE122008000050C 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung Active DE122008000050I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34861496 1996-12-26
JP7405497 1997-03-26
JP17247797 1997-06-27

Publications (2)

Publication Number Publication Date
DE122008000050I1 DE122008000050I1 (de) 2009-01-29
DE122008000050I2 true DE122008000050I2 (de) 2011-06-16

Family

ID=27301396

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122008000050C Active DE122008000050I2 (de) 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung
DE69716226T Expired - Lifetime DE69716226T2 (de) 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69716226T Expired - Lifetime DE69716226T2 (de) 1996-12-26 1997-12-22 Difluoroprostaglandin-Derivate und ihre Anwendung

Country Status (16)

Country Link
US (2) US5886035A (enExample)
EP (1) EP0850926B1 (enExample)
JP (2) JP3480549B2 (enExample)
KR (1) KR100526282B1 (enExample)
CN (1) CN1108289C (enExample)
AT (1) ATE225770T1 (enExample)
CA (1) CA2225761C (enExample)
DE (2) DE122008000050I2 (enExample)
DK (1) DK0850926T3 (enExample)
ES (1) ES2187719T3 (enExample)
FR (1) FR11C0020I2 (enExample)
LU (1) LU91943I2 (enExample)
NL (1) NL300407I2 (enExample)
NO (2) NO317060B1 (enExample)
PT (1) PT850926E (enExample)
TW (1) TW536534B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
IL134241A (en) * 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
AU2001228836A1 (en) * 2000-01-28 2001-08-07 Santen Pharmaceutical Co., Ltd. Novel difluoroprostaglandin derivative
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
ATE374031T1 (de) * 2002-08-23 2007-10-15 Santen Pharmaceutical Co Ltd Stabile augentropfen enthaltend latanoprost als wirkstoff
KR101253941B1 (ko) 2002-09-09 2013-04-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
WO2005011704A1 (ja) * 2003-07-31 2005-02-10 Santen Pharmaceutical Co., Ltd. プロスタグランジン含有製品
EP2247071B1 (en) * 2003-12-08 2013-09-25 QUALCOMM Incorporated High data rate interface with improved link synchronization
WO2006062184A1 (ja) * 2004-12-09 2006-06-15 Santen Pharmaceutical Co., Ltd. 分子内にフッ素原子を有するプロスタグランジン含有製品
JP4753178B2 (ja) * 2004-12-24 2011-08-24 参天製薬株式会社 プロスタグランジンＦ２α誘導体含有製品
JP5100025B2 (ja) * 2005-03-31 2012-12-19 旭硝子株式会社 プロスタグランジンＦ２α誘導体を有効成分として含む網膜神経細胞保護剤
EP1864666B1 (en) * 2005-03-31 2012-08-15 Asahi Glass Company, Limited Protective agent for retinal neuronal cell containing prostaglandin f2 alpha derivative as active ingredient
JPWO2006112313A1 (ja) 2005-04-13 2008-12-11 宇部興産株式会社 インダゾール誘導体を有効成分として含む網膜神経細胞保護剤
WO2007000642A1 (en) * 2005-06-29 2007-01-04 Pfizer Inc. Fluoroprostaglandins nitroderivatives
CA2637797C (en) * 2006-02-07 2015-03-17 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
FR2918891B1 (fr) * 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
JP5645381B2 (ja) * 2008-09-04 2014-12-24 参天製薬株式会社 １５，１５−ジフルオロプロスタグランジンＦ２α誘導体を有効成分として含有する毛髪成長促進剤
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
BR112013002584A2 (pt) 2010-08-02 2016-06-07 Pharma Patent Holding Inc composição, processo de kit para aperfeiçoamento de cabelo
ES2687494T3 (es) 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal
TW201729813A (zh) 2011-02-04 2017-09-01 Kowa Co Ltd 青光眼預防或治療之藥物療法
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
WO2013118058A1 (en) * 2012-02-07 2013-08-15 Dr.Reddys Laboratories Limited Amine salts of prostaglandin analogs
WO2013180229A1 (ja) 2012-05-30 2013-12-05 旭硝子株式会社 育毛用組成物
CA2869676C (en) 2012-11-21 2015-06-23 Topokine Therapeutics, Inc. Uses and compositions comprising a thiazolidinedione and oleic acid for locally increasing subcutaneous fat
NO2753788T3 (enExample) 2013-05-10 2018-06-16
WO2014186504A1 (en) 2013-05-15 2014-11-20 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
CN103570549B (zh) * 2013-10-11 2016-01-27 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103804195B (zh) * 2014-01-26 2016-06-15 天泽恩源（天津）制药有限公司 一种合成他氟前列素的方法
CN103819436A (zh) * 2014-02-21 2014-05-28 天泽恩源（天津）医药技术有限公司 (3aR,4R,5R,6aS)-4-((E)-3,3-二氟-4-苯氧基丁-1-烯-1-基)-2-氧代六氢-2H-环戊烷[b]呋喃-5-基苯甲酸酯的一种晶型及相应晶体的制备方法
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
KR20160116402A (ko) 2015-03-30 2016-10-10 연성정밀화학(주) 타플루프로스트의 제조방법
EA037327B1 (ru) 2015-09-22 2021-03-12 Грейбуг Вижн, Инк. Соединения и композиции для лечения глазных расстройств
CN107226790A (zh) * 2016-03-25 2017-10-03 苏州朗科生物技术有限公司 一种高纯度他氟前列素及其类似化合物的制备方法及中间体化合物
GR1009040B (el) 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
CN108299192A (zh) * 2017-01-10 2018-07-20 江苏恒瑞医药股份有限公司 一种他氟前列素酸的金属盐化合物结晶形式及其制备方法
CN106986766B (zh) * 2017-05-08 2021-01-12 扬子江药业集团有限公司 他氟前列素的制备方法
CN112457277B (zh) * 2020-12-16 2022-06-28 西安国康瑞金制药有限公司 一种他氟前列腺素的制备方法
CN112832150B (zh) * 2021-01-27 2022-06-24 中交第三公路工程局有限公司 一种涵洞通道等立面垂直凿毛装置
CN112851510B (zh) * 2021-01-27 2022-07-19 Ａｇｃ株式会社 他氟前列素的纯化方法
CN116120268A (zh) * 2023-03-06 2023-05-16 南京华威医药科技集团有限公司 一种他氟前列素中间体杂质及其制备方法
CN116425707A (zh) * 2023-03-31 2023-07-14 南京华威医药科技集团有限公司 一种他氟前列素中间体异构体杂质及其制备方法
CN117024324A (zh) * 2023-08-03 2023-11-10 南京华威医药科技集团有限公司 一种他氟前列素对映异构体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
WO1998021181A2 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc. 15-fluoro prostaglandins as ocular hypotensives

Also Published As

Publication number Publication date
US5985920A (en) 1999-11-16
ATE225770T1 (de) 2002-10-15
FR11C0020I1 (enExample) 2011-07-29
NO317060B1 (no) 2004-08-02
CA2225761A1 (en) 1998-06-26
PT850926E (pt) 2003-02-28
KR19980064718A (ko) 1998-10-07
DK0850926T3 (da) 2003-02-17
EP0850926A3 (en) 1999-06-16
NO2009006I2 (no) 2012-03-05
JP2004002462A (ja) 2004-01-08
DE69716226D1 (de) 2002-11-14
LU91943I2 (fr) 2012-04-16
DE122008000050I1 (de) 2009-01-29
NO2009006I1 (no) 2009-03-16
CN1187486A (zh) 1998-07-15
EP0850926A2 (en) 1998-07-01
NL300407I2 (nl) 2010-03-01
JPH1171344A (ja) 1999-03-16
ES2187719T3 (es) 2003-06-16
DE69716226T2 (de) 2003-06-05
JP3480549B2 (ja) 2003-12-22
FR11C0020I2 (fr) 2012-03-16
TW536534B (en) 2003-06-11
KR100526282B1 (ko) 2006-05-17
NO976085L (no) 1998-06-29
JP3994074B2 (ja) 2007-10-17
EP0850926B1 (en) 2002-10-09
CA2225761C (en) 2009-04-21
US5886035A (en) 1999-03-23
NO976085D0 (no) 1997-12-23
NL300407I1 (nl) 2009-11-02
CN1108289C (zh) 2003-05-14

Similar Documents

Publication Publication Date Title
DE69716226D1 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
DE69418243D1 (de) N-Heteroaryl-N'-Phenylharnstoffderivate, ihre Herstellung und Verwendung
KR970069985A (ko) 1,2-디페닐피롤 유도체,그의 제법 및 그의 치료학적 용도
PT918776E (pt) Sintese total de acilfulvenos antitumorais
DK0695755T3 (da) Pyrrolocarbazoler
ATE158795T1 (de) Thiazolidindionderivate, ihre herstellung und anwendung
DE69623497D1 (de) 1-methylcarbapenem-derivate
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
EP1034783A4 (en) AMIDE DERIVATIVES
FI956151A0 (fi) Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
DE69123757D1 (de) Epoxysuccinamidsäurederivat
DE69202594D1 (de) Zusammensetzung gegen Katarakt.
ATE71364T1 (de) Fluor enthaltende vitamin-d2-derivate.
DE3782229D1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ES2115303T3 (es) Uso de compuestos de 5-tia-1,4-diazabiciclo(4.2.0)octan-3,8-dioxo en terapia antitumoral.